Ubs Group Ag Adaptimmune Therapeutics PLC Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Ubs Group Ag holds 6,667,358 shares of ADAP stock, worth $200,020. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,667,358

Previous 62,958 10490.17%

Holding current value

$200,020

Previous $15,000 6120.0%

% of portfolio

0.0%

Previous 0.0%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$0.04 - $0.35 $264,176 - $2.31 Million	6,604,400 Added 10490.17%	6,667,358 $933,000
Q2 2025 Aug 14, 2025	SELL	$0.22 - $0.32 $208,952 - $303,930	-949,782 Reduced 93.78%	62,958 $15,000
Q1 2025 May 13, 2025	BUY	$0.2 - $0.65 $174,199 - $566,147	870,996 Added 614.49%	1,012,740 $202,000
Q4 2024 Feb 14, 2025	BUY	$0.54 - $0.95 $75,560 - $132,930	139,927 Added 7700.99%	141,744 $76,000
Q2 2024 Aug 13, 2024	SELL	$0.83 - $1.47 $161,749 - $286,472	-194,879 Reduced 99.08%	1,817 $1,000

Q1 2024 May 13, 2024	BUY	$0.7 - $1.75 $120,402 - $301,005	172,003 Added 696.57%	196,696 $310,000
Q4 2023 Feb 09, 2024	SELL	$0.43 - $0.79 $1,565 - $2,876	-3,641 Reduced 12.85%	24,693 $19,000
Q3 2023 Nov 09, 2023	SELL	$0.73 - $1.04 $1,931 - $2,751	-2,646 Reduced 8.54%	28,334 $22,000
Q2 2023 Aug 11, 2023	BUY	$0.9 - $1.51 $3,807 - $6,387	4,230 Added 15.81%	30,980 $28,000
Q1 2023 May 12, 2023	BUY	$1.06 - $2.16 $3,312 - $6,750	3,125 Added 13.23%	26,750 $29,000
Q4 2022 Feb 08, 2023	BUY	$1.05 - $2.53 $22,723 - $54,751	21,641 Added 1090.78%	23,625 $34,000
Q3 2022 Nov 10, 2022	SELL	$1.06 - $2.41 $2,883 - $6,555	-2,720 Reduced 57.82%	1,984 $2,000
Q2 2022 Aug 10, 2022	SELL	$1.33 - $2.28 $1,048 - $1,796	-788 Reduced 14.35%	4,704 $8,000
Q1 2022 May 16, 2022	SELL	$1.73 - $4.06 $19,168 - $44,984	-11,080 Reduced 66.86%	5,492 $12,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $5.68 $3,734 - $6,060	1,067 Added 6.88%	16,572 $61,000
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $5,479 - $10,147	1,593 Added 11.45%	15,505 $80,000
Q2 2021 Aug 13, 2021	SELL	$3.86 - $5.78 $672,303 - $1.01 Million	-174,172 Reduced 92.6%	13,912 $60,000
Q1 2021 May 12, 2021	BUY	$4.9 - $6.83 $31,859 - $44,408	6,502 Added 3.58%	188,084 $998,000
Q4 2020 Feb 11, 2021	BUY	$4.0 - $9.2 $224,996 - $517,490	56,249 Added 44.88%	181,582 $978,000
Q3 2020 Nov 12, 2020	BUY	$7.66 - $10.78 $959,514 - $1.35 Million	125,263 Added 178947.14%	125,333 $1 Million
Q2 2020 Jul 31, 2020	SELL	$2.58 - $12.1 $12,938 - $60,681	-5,015 Reduced 98.62%	70 $1,000
Q1 2020 May 01, 2020	SELL	$1.2 - $4.52 $1,370 - $5,161	-1,142 Reduced 18.34%	5,085 $14,000
Q4 2019 Feb 14, 2020	BUY	$0.72 - $1.43 $4,433 - $8,804	6,157 Added 8795.71%	6,227 $7,000
Q3 2019 Nov 14, 2019	SELL	$1.43 - $3.81 $11,482 - $30,594	-8,030 Reduced 99.14%	70 $0
Q2 2019 Aug 14, 2019	BUY	$3.23 - $5.41 $8,494 - $14,228	2,630 Added 48.08%	8,100 $32,000
Q1 2019 May 14, 2019	SELL	$3.63 - $6.06 $7,623 - $12,726	-2,100 Reduced 27.74%	5,470 $24,000
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $414,570 - $1.56 Million	-110,258 Reduced 93.58%	7,570 $44,000
Q3 2018 Nov 14, 2018	BUY	$8.27 - $13.56 $878,025 - $1.44 Million	106,170 Added 910.71%	117,828 $1.6 Million
Q2 2018 Aug 14, 2018	BUY	$10.42 - $13.74 $85,735 - $113,052	8,228 Added 239.88%	11,658 $138,000
Q1 2018 May 15, 2018	SELL	$7.1 - $11.56 $17,515 - $28,518	-2,467 Reduced 41.83%	3,430 $38,000
Q4 2017 Feb 14, 2018	BUY	$6.68 - $8.74 $29,371 - $38,429	4,397 Added 293.13%	5,897 $39,000
Q3 2017 Nov 14, 2017	SELL	$4.93 - $8.93 $2,465 - $4,465	-500 Reduced 25.0%	1,500 $12,000
Q2 2017 Aug 14, 2017	BUY	N/A	1,228 Added 159.07%	2,000 $9,000
Q1 2017 Nov 14, 2017	BUY	N/A	772	772 $4,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

42M

Call Options Held

139K

Put Options Held

144K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $4.9M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account